Mobility key to quality of life for MS sufferers

May 18, 2012

(Medical Xpress) -- Reduced mobility among patients with secondary‐progressive multiple sclerosis (SPMS) is associated with a decline in quality of life, according to new data presented today at the 7th World Congress of NeuroRehabilitation in Melbourne.

According to  UNSW's Associate Professor of Neuroscience, Arun Krishnan, whether or not symptomatic treatments that improve might also make a positive contribution to ’ quality of life is an important focus for future research.

Professor Krishnan’s research looked at data derived from 160 placebo treated MS patients whose speed was measured using the Timed 25 Foot Walk (T25FW) test and then correlated this with quality of life measures (including a physical component summary scale, physical function, bodily pain and general health) over a two year period.

Overall, slower walking speed was associated with a decline in quality of life over two years. This association between walking speed and quality of life was independent of any treatment because the subjects were derived from the placebo arm of a clinical trial.

At two years, data showed that patients walked on average 19% slower. Physical component scores (like physical function and general health) declined in patients who walked more than 0.15 metres/second slower at month 24 compared with baseline and improved in the small number who walked greater than 0.15 metres/second faster.

Professor Krishnan says the findings are important as they suggest a clinical focus on the treatment of reduced mobility in MS patients might deliver significant benefits in the future to patients with secondary‐progressive .

“There are limited treatment options for patients whose MS is progressing and who are at the ‘secondary progressive’ phase. Whether treatments that improve walking also positively influence health‐related quality of life in MS patients is certainly an intriguing question for the future,” said Professor Krishnan.

Explore further: New MRI finding sheds light on multiple sclerosis disease progression

Related Stories

Smoking marijuana impairs cognitive function in MS patients

February 13, 2008

People with multiple sclerosis (MS) who smoke marijuana are more likely to have emotional and memory problems, according to research published February 13, 2008, in the online edition of Neurology, the medical journal of ...

Quality of life predicts cancer survival

May 29, 2008

Head and neck cancer patients who reported lower physical quality of life were more likely to die from their disease, according to a new study from the University of Michigan Comprehensive Cancer Center. The findings could ...

Drug improves mobility for some MS patients

February 27, 2009

The experimental drug fampridine (4-aminopyridine) improves walking ability in some individuals with multiple sclerosis (MS). That is the conclusion of a multi-center Phase 3 clinical trial, the results of which were published ...

Muscling in on multiple sclerosis

January 26, 2012

Multiple sclerosis (MS), a neurodegenerative disease, causes periodic attacks of neurologic symptoms such as limb weakness and mobility defects. And while MS patients' walking abilities and muscle strength are examined on ...

Recommended for you

Researchers discover a drug for a tropical disease

August 30, 2016

Researchers at the University of Georgia are working to find the fastest way possible to treat and cure human African trypanosomiasis, long referred to as sleeping sickness. By working to improve chemical entities already ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.